Pre-Approval Access to Amivantamab in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations who have Failed Platinum-Based Chemotherapy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Has histologically or cytologically confirmed unresectable or metastatic NSCLC with an EGFR Exon20ins, not amenable to curative therapy. 2) Has completed prior treatment with platinum-based chemotherapy. Note: Platinum ineligible patients may qualify if treated with an alternative treatment. 3) Life expectancy is projected to be >= 3 months with adequate hepatic, renal, pulmonary and cardiac function (physician assessed).

You may not be eligible for this study if the following are true:

  • 1) Has medical history of interstitial lung disease (ILD including drug induced ILD or radiation pneumonitis requiring treatment with prolonged steroids or other immune suppressive agents with in the last 3 months. 2) Has a toxicity from prior anticancer therapy (e.g. rash that has not re solved to Grade 1 or 0 or has reached stability with no further improvements excepted. 3) Has leptomeningeal disease that is active or symptomatic. 4) Symptomatic, unstable or untreated brain metastases (need to be resolved prior to participating in the program).


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.